Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
1.
J Clin Invest ; 133(4)2023 02 15.
Article in English | MEDLINE | ID: mdl-36787249

ABSTRACT

BACKGROUNDMosaic and consensus HIV-1 immunogens provide two distinct approaches to elicit greater breadth of coverage against globally circulating HIV-1 and have shown improved immunologic breadth in nonhuman primate models.METHODSThis double-blind randomized trial enrolled 105 healthy HIV-uninfected adults who received 3 doses of either a trivalent global mosaic, a group M consensus (CON-S), or a natural clade B (Nat-B) gp160 env DNA vaccine followed by 2 doses of a heterologous modified vaccinia Ankara-vectored HIV-1 vaccine or placebo. We performed prespecified blinded immunogenicity analyses at day 70 and day 238 after the first immunization. T cell responses to vaccine antigens and 5 heterologous Env variants were fully mapped.RESULTSEnv-specific CD4+ T cell responses were induced in 71% of the mosaic vaccine recipients versus 48% of the CON-S recipients and 48% of the natural Env recipients. The mean number of T cell epitopes recognized was 2.5 (95% CI, 1.2-4.2) for mosaic recipients, 1.6 (95% CI, 0.82-2.6) for CON-S recipients, and 1.1 (95% CI, 0.62-1.71) for Nat-B recipients. Mean breadth was significantly greater in the mosaic group than in the Nat-B group using overall (P = 0.014), prime-matched (P = 0.002), heterologous (P = 0.046), and boost-matched (P = 0.009) measures. Overall T cell breadth was largely due to Env-specific CD4+ T cell responses.CONCLUSIONPriming with a mosaic antigen significantly increased the number of epitopes recognized by Env-specific T cells and enabled more, albeit still limited, cross-recognition of heterologous variants. Mosaic and consensus immunogens are promising approaches to address global diversity of HIV-1.TRIAL REGISTRATIONClinicalTrials.gov NCT02296541.FUNDINGUS NIH grants UM1 AI068614, UM1 AI068635, UM1 AI068618, UM1 AI069412, UL1 RR025758, P30 AI064518, UM1 AI100645, and UM1 AI144371, and Bill & Melinda Gates Foundation grant OPP52282.


Subject(s)
AIDS Vaccines , HIV Infections , Vaccines, DNA , Animals , Consensus , Immunity, Cellular , Vaccination , Vaccinia virus , HIV Antibodies
2.
PLOS Glob Public Health ; 2(2): e0000207, 2022.
Article in English | MEDLINE | ID: mdl-36962401

ABSTRACT

Viral pathogens can rapidly evolve, adapt to novel hosts, and evade human immunity. The early detection of emerging viral pathogens through biosurveillance coupled with rapid and accurate diagnostics are required to mitigate global pandemics. However, RNA viruses can mutate rapidly, hampering biosurveillance and diagnostic efforts. Here, we present a novel computational approach called FEVER (Fast Evaluation of Viral Emerging Risks) to design assays that simultaneously accomplish: 1) broad-coverage biosurveillance of an entire group of viruses, 2) accurate diagnosis of an outbreak strain, and 3) mutation typing to detect variants of public health importance. We demonstrate the application of FEVER to generate assays to simultaneously 1) detect sarbecoviruses for biosurveillance; 2) diagnose infections specifically caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); and 3) perform rapid mutation typing of the D614G SARS-CoV-2 spike variant associated with increased pathogen transmissibility. These FEVER assays had a high in silico recall (predicted positive) up to 99.7% of 525,708 SARS-CoV-2 sequences analyzed and displayed sensitivities and specificities as high as 92.4% and 100% respectively when validated in 100 clinical samples. The D614G SARS-CoV-2 spike mutation PCR test was able to identify the single nucleotide identity at position 23,403 in the viral genome of 96.6% SARS-CoV-2 positive samples without the need for sequencing. This study demonstrates the utility of FEVER to design assays for biosurveillance, diagnostics, and mutation typing to rapidly detect, track, and mitigate future outbreaks and pandemics caused by emerging viruses.

3.
Biosensors (Basel) ; 11(10)2021 Sep 30.
Article in English | MEDLINE | ID: mdl-34677323

ABSTRACT

Detection methods that do not require nucleic acid amplification are advantageous for viral diagnostics due to their rapid results. These platforms could provide information for both accurate diagnoses and pandemic surveillance. Influenza virus is prone to pandemic-inducing genetic mutations, so there is a need to apply these detection platforms to influenza diagnostics. Here, we analyzed the Fast Evaluation of Viral Emerging Risks (FEVER) pipeline on ultrasensitive detection platforms, including a waveguide-based optical biosensor and a flow cytometry bead-based assay. The pipeline was also evaluated in silico for sequence coverage in comparison to the U.S. Centers for Disease Control and Prevention's (CDC) influenza A and B diagnostic assays. The influenza FEVER probe design had a higher tolerance for mismatched bases than the CDC's probes, and the FEVER probes altogether had a higher detection rate for influenza isolate sequences from GenBank. When formatted for use as molecular beacons, the FEVER probes detected influenza RNA as low as 50 nM on the waveguide-based optical biosensor and 1 nM on the flow cytometer. In addition to molecular beacons, which have an inherently high background signal we also developed an exonuclease selection method that could detect 500 pM of RNA. The combination of high-coverage probes developed using the FEVER pipeline coupled with ultrasensitive optical biosensors is a promising approach for future influenza diagnostic and biosurveillance applications.


Subject(s)
Influenza, Human , Nucleic Acid Amplification Techniques , Biosensing Techniques , Humans , Orthomyxoviridae , RNA , Sensitivity and Specificity
5.
Cell Host Microbe ; 25(1): 59-72.e8, 2019 01 09.
Article in English | MEDLINE | ID: mdl-30629920

ABSTRACT

Eliciting HIV-1-specific broadly neutralizing antibodies (bNAbs) remains a challenge for vaccine development, and the potential of passively delivered bNAbs for prophylaxis and therapeutics is being explored. We used neutralization data from four large virus panels to comprehensively map viral signatures associated with bNAb sensitivity, including amino acids, hypervariable region characteristics, and clade effects across four different classes of bNAbs. The bNAb signatures defined for the variable loop 2 (V2) epitope region of HIV-1 Env were then employed to inform immunogen design in a proof-of-concept exploration of signature-based epitope targeted (SET) vaccines. V2 bNAb signature-guided mutations were introduced into Env 459C to create a trivalent vaccine, and immunization of guinea pigs with V2-SET vaccines resulted in increased breadth of NAb responses compared with Env 459C alone. These data demonstrate that bNAb signatures can be utilized to engineer HIV-1 Env vaccine immunogens capable of eliciting antibody responses with greater neutralization breadth.


Subject(s)
Antibodies, Neutralizing/immunology , Epitopes/immunology , HIV Antibodies/immunology , HIV Infections/immunology , HIV Infections/prevention & control , Vaccines , Amino Acid Sequence , Animals , Antibodies, Neutralizing/therapeutic use , Antibody Formation , Disease Models, Animal , Epitopes/genetics , Female , Guinea Pigs , HEK293 Cells , HIV Envelope Protein gp120/immunology , HIV Infections/virology , HIV-1/genetics , Humans , Immunization , Inhibitory Concentration 50 , Models, Molecular , Mutation , Peptide Fragments/immunology , Protein Binding , Vaccination , env Gene Products, Human Immunodeficiency Virus/genetics , env Gene Products, Human Immunodeficiency Virus/immunology
6.
PLoS Pathog ; 14(4): e1006944, 2018 04.
Article in English | MEDLINE | ID: mdl-29672607

ABSTRACT

Despite extensive genetic diversity of HIV-1 in chronic infection, a single or few maternal virus variants become the founders of an infant's infection. These transmitted/founder (T/F) variants are of particular interest, as a maternal or infant HIV vaccine should raise envelope (Env) specific IgG responses capable of blocking this group of viruses. However, the maternal or infant factors that contribute to selection of infant T/F viruses are not well understood. In this study, we amplified HIV-1 env genes by single genome amplification from 16 mother-infant transmitting pairs from the U.S. pre-antiretroviral era Women Infant Transmission Study (WITS). Infant T/F and representative maternal non-transmitted Env variants from plasma were identified and used to generate pseudoviruses for paired maternal plasma neutralization sensitivity analysis. Eighteen out of 21 (85%) infant T/F Env pseudoviruses were neutralization resistant to paired maternal plasma. Yet, all infant T/F viruses were neutralization sensitive to a panel of HIV-1 broadly neutralizing antibodies and variably sensitive to heterologous plasma neutralizing antibodies. Also, these infant T/F pseudoviruses were overall more neutralization resistant to paired maternal plasma in comparison to pseudoviruses from maternal non-transmitted variants (p = 0.012). Altogether, our findings suggest that autologous neutralization of circulating viruses by maternal plasma antibodies select for neutralization-resistant viruses that initiate peripartum transmission, raising the speculation that enhancement of this response at the end of pregnancy could further reduce infant HIV-1 infection risk.


Subject(s)
Antibodies, Neutralizing/immunology , HIV Infections/transmission , HIV-1/genetics , Infectious Disease Transmission, Vertical , Plasma/metabolism , Pregnancy Complications, Infectious/etiology , env Gene Products, Human Immunodeficiency Virus/immunology , Female , Genetic Variation , HIV Antibodies/immunology , HIV Infections/immunology , HIV Infections/virology , Humans , Infant , Neutralization Tests , Peripartum Period , Pregnancy , Pregnancy Complications, Infectious/metabolism , env Gene Products, Human Immunodeficiency Virus/genetics
7.
Sci Rep ; 6: 33987, 2016 10 05.
Article in English | MEDLINE | ID: mdl-27703185

ABSTRACT

Epigraph is an efficient graph-based algorithm for designing vaccine antigens to optimize potential T-cell epitope (PTE) coverage. Epigraph vaccine antigens are functionally similar to Mosaic vaccines, which have demonstrated effectiveness in preliminary HIV non-human primate studies. In contrast to the Mosaic algorithm, Epigraph is substantially faster, and in restricted cases, provides a mathematically optimal solution. Epigraph furthermore has new features that enable enhanced vaccine design flexibility. These features include the ability to exclude rare epitopes from a design, to optimize population coverage based on inexact epitope matches, and to apply the code to both aligned and unaligned input sequences. Epigraph was developed to provide practical design solutions for two outstanding vaccine problems. The first of these is a personalized approach to a therapeutic T-cell HIV vaccine that would provide antigens with an excellent match to an individual's infecting strain, intended to contain or clear a chronic infection. The second is a pan-filovirus vaccine, with the potential to protect against all known viruses in the Filoviradae family, including ebolaviruses. A web-based interface to run the Epigraph tool suite is available (http://www.hiv.lanl.gov/content/sequence/EPIGRAPH/epigraph.html).


Subject(s)
AIDS Vaccines , Epitopes , Filoviridae Infections , HIV Infections , HIV-1 , Sequence Analysis, Protein/methods , Software , AIDS Vaccines/genetics , AIDS Vaccines/immunology , Epitopes/genetics , Epitopes/immunology , Filoviridae/genetics , Filoviridae/immunology , Filoviridae Infections/genetics , Filoviridae Infections/immunology , Filoviridae Infections/therapy , HIV Infections/genetics , HIV Infections/immunology , HIV Infections/therapy , HIV-1/genetics , HIV-1/immunology , Humans
8.
Article in English | MEDLINE | ID: mdl-27103629

ABSTRACT

The Ebola outbreak of 2013-15 infected more than 28 000 people and claimed more lives than all previous filovirus outbreaks combined. Governmental agencies, clinical teams, and the world scientific community pulled together in a multifaceted response ranging from prevention and disease control, to evaluating vaccines and therapeutics in human trials. As this epidemic is finally coming to a close, refocusing on long-term prevention strategies becomes paramount. Given the very real threat of future filovirus outbreaks, and the inherent uncertainty of the next outbreak virus and geographic location, it is prudent to consider the extent and implications of known natural diversity in advancing vaccines and therapeutic approaches. To facilitate such consideration, we have updated and enhanced the content of the filovirus portion of Los Alamos Hemorrhagic Fever Viruses Database. We have integrated and performed baseline analysis of all family ITALIC! Filoviridaesequences deposited into GenBank, with associated immune response data, and metadata, and we have added new computational tools with web-interfaces to assist users with analysis. Here, we (i) describe the main features of updated database, (ii) provide integrated views and some basic analyses summarizing evolutionary patterns as they relate to geo-temporal data captured in the database and (iii) highlight the most conserved regions in the proteome that may be useful for a T cell vaccine strategy.Database URL:www.hfv.lanl.gov.


Subject(s)
Databases, Genetic , Filoviridae Infections/virology , Filoviridae/genetics , Filoviridae/immunology , Filoviridae Infections/immunology , Humans , Internet , New Mexico , User-Computer Interface
9.
Nucleic Acids Res ; 43(W1): W213-9, 2015 Jul 01.
Article in English | MEDLINE | ID: mdl-26044712

ABSTRACT

CATNAP (Compile, Analyze and Tally NAb Panels) is a new web server at Los Alamos HIV Database, created to respond to the newest advances in HIV neutralizing antibody research. It is a comprehensive platform focusing on neutralizing antibody potencies in conjunction with viral sequences. CATNAP integrates neutralization and sequence data from published studies, and allows users to analyze that data for each HIV Envelope protein sequence position and each antibody. The tool has multiple data retrieval and analysis options. As input, the user can pick specific antibodies and viruses, choose a panel from a published study, or supply their own data. The output superimposes neutralization panel data, virus epidemiological data, and viral protein sequence alignments on one page, and provides further information and analyses. The user can highlight alignment positions, or select antibody contact residues and view position-specific information from the HIV databases. The tool calculates tallies of amino acids and N-linked glycosylation motifs, counts of antibody-sensitive and -resistant viruses in conjunction with each amino acid or N-glycosylation motif, and performs Fisher's exact test to detect potential positive or negative amino acid associations for the selected antibody. Website name: CATNAP (Compile, Analyze and Tally NAb Panels). Website address: http://hiv.lanl.gov/catnap.


Subject(s)
Antibodies, Neutralizing/pharmacology , HIV Antibodies/pharmacology , Software , Human Immunodeficiency Virus Proteins/chemistry , Inhibitory Concentration 50 , Internet , Sequence Analysis, Protein , Viral Envelope Proteins/chemistry
10.
J Infect Dis ; 211(6): 936-46, 2015 Mar 15.
Article in English | MEDLINE | ID: mdl-25249264

ABSTRACT

The characterization of host immune responses to human immunodeficiency virus (HIV) in HIV controllers and individuals with high exposure but seronegativity to HIV (HESN) is needed to guide the development of effective preventive and therapeutic vaccine candidates. However, several technical hurdles severely limit the definition of an effective virus-specific T-cell response. By using a toggle-peptide approach, which takes HIV sequence diversity into account, and a novel, boosted cytokine staining/flow cytometry strategy, we here describe new patterns of T-cell responses to HIV that would be missed by standard assays. Importantly, this approach also allows detection of broad and strong virus-specific T-cell responses in HESN individuals that are characterized by a T-helper type 1 cytokine-like effector profile and produce cytokines that have been associated with potential control of HIV infection, including interleukin 10, interleukin 13, and interleukin 22. These results establish a novel approach to improve the current understanding of HIV-specific T-cell immunity and identify cellular immune responses and individual cytokines as potential markers of relative HIV resistance. As such, the findings also help develop similar strategies for more-comprehensive assessments of host immune responses to other human infections and immune-mediated disorders.


Subject(s)
HIV/immunology , T-Lymphocytes, Helper-Inducer/immunology , Cells, Cultured , Cytokines/metabolism , Disease Resistance , Humans , Immunity, Cellular , T-Lymphocytes, Helper-Inducer/metabolism , T-Lymphocytes, Helper-Inducer/virology
11.
J Virol ; 89(5): 2507-19, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25540368

ABSTRACT

UNLABELLED: The sequence diversity of human immunodeficiency virus type 1 (HIV-1) presents a formidable challenge to the generation of an HIV-1 vaccine. One strategy to address such sequence diversity and to improve the magnitude of neutralizing antibodies (NAbs) is to utilize multivalent mixtures of HIV-1 envelope (Env) immunogens. Here we report the generation and characterization of three novel, acute clade C HIV-1 Env gp140 trimers (459C, 405C, and 939C), each with unique antigenic properties. Among the single trimers tested, 459C elicited the most potent NAb responses in vaccinated guinea pigs. We evaluated the immunogenicity of various mixtures of clade C Env trimers and found that a quadrivalent cocktail of clade C trimers elicited a greater magnitude of NAbs against a panel of tier 1A and 1B viruses than any single clade C trimer alone, demonstrating that the mixture had an advantage over all individual components of the cocktail. These data suggest that vaccination with a mixture of clade C Env trimers represents a promising strategy to augment vaccine-elicited NAb responses. IMPORTANCE: It is currently not known how to generate potent NAbs to the diverse circulating HIV-1 Envs by vaccination. One strategy to address this diversity is to utilize mixtures of different soluble HIV-1 envelope proteins. In this study, we generated and characterized three distinct, novel, acute clade C soluble trimers. We vaccinated guinea pigs with single trimers as well as mixtures of trimers, and we found that a mixture of four trimers elicited a greater magnitude of NAbs than any single trimer within the mixture. The results of this study suggest that further development of Env trimer cocktails is warranted.


Subject(s)
AIDS Vaccines/immunology , Antibodies, Neutralizing/blood , HIV Antibodies/blood , HIV-1/immunology , Vaccination/methods , env Gene Products, Human Immunodeficiency Virus/immunology , AIDS Vaccines/administration & dosage , Animals , Female , Guinea Pigs , Treatment Outcome
12.
Mol Microbiol ; 91(6): 1106-19, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24417450

ABSTRACT

Rifampicin resistance, a defining attribute of multidrug-resistant tuberculosis, is conferred by mutations in the ß subunit of RNA polymerase. Sequencing of rifampicin-resistant (RIF-R) clinical isolates of Mycobacterium tuberculosis revealed, in addition to RIF-R mutations, enrichment of potential compensatory mutations around the double-psi ß-barrel domain of the ß' subunit comprising the catalytic site and the exit tunnel for newly synthesized RNA. Sequential introduction of the resistance allele followed by the compensatory allele in isogenic Mycobacterium smegmatis showed that these mutations respectively caused and compensated a starvation enhanced growth defect by altering RNA polymerase activity. While specific combinations of resistance and compensatory alleles converged in divergent lineages, other combinations recurred among related isolates suggesting transmission of compensated RIF-R strains. These findings suggest nutrient poor growth conditions impose larger selective pressure on RIF-R organisms that results in the selection of compensatory mutations in a domain involved in catalysis and starvation control of RNA polymerase transcription.


Subject(s)
Antitubercular Agents/pharmacology , DNA-Directed RNA Polymerases/genetics , Drug Resistance, Bacterial , Mutation, Missense , Mycobacterium smegmatis/growth & development , Mycobacterium smegmatis/metabolism , Rifampin/pharmacology , DNA-Directed RNA Polymerases/metabolism , Mycobacterium smegmatis/drug effects , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/growth & development
13.
Clin Vaccine Immunol ; 20(2): 302-5, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23221002

ABSTRACT

Despite improved hepatitis C virus (HCV) treatments, vaccines remain an effective and economic option for curtailing the epidemic. Mosaic protein HCV genotype 1 vaccine candidates designed to address HCV diversity were immunogenic in mice. They elicited stronger T-cell responses to NS3-NS4a and E1-E2 proteins than did natural strains, as assessed with vaccine-matched peptides.


Subject(s)
Hepacivirus/immunology , Hepatitis C/immunology , T-Lymphocytes/immunology , Viral Hepatitis Vaccines/immunology , Animals , Antibodies, Viral/immunology , Hepacivirus/genetics , Hepatitis C/prevention & control , Mice , Mice, Inbred BALB C , Vaccination , Vaccines, Synthetic , Viral Envelope Proteins/immunology , Viral Hepatitis Vaccines/administration & dosage , Viral Hepatitis Vaccines/genetics , Viral Nonstructural Proteins/immunology
14.
PLoS One ; 7(10): e44769, 2012.
Article in English | MEDLINE | ID: mdl-23056184

ABSTRACT

We report the rational design and in vivo testing of mosaic proteins for a polyvalent pan-filoviral vaccine using a computational strategy designed for the Human Immunodeficiency Virus type 1 (HIV-1) but also appropriate for Hepatitis C virus (HCV) and potentially other diverse viruses. Mosaics are sets of artificial recombinant proteins that are based on natural proteins. The recombinants are computationally selected using a genetic algorithm to optimize the coverage of potential cytotoxic T lymphocyte (CTL) epitopes. Because evolutionary history differs markedly between HIV-1 and filoviruses, we devised an adapted computational technique that is effective for sparsely sampled taxa; our first significant result is that the mosaic technique is effective in creating high-quality mosaic filovirus proteins. The resulting coverage of potential epitopes across filovirus species is superior to coverage by any natural variants, including current vaccine strains with demonstrated cross-reactivity. The mosaic cocktails are also robust: mosaics substantially outperformed natural strains when computationally tested against poorly sampled species and more variable genes. Furthermore, in a computational comparison of cross-reactive potential a design constructed prior to the Bundibugyo outbreak performed nearly as well against all species as an updated design that included Bundibugyo. These points suggest that the mosaic designs would be more resilient than natural-variant vaccines against future Ebola outbreaks dominated by novel viral variants. We demonstrate in vivo immunogenicity and protection against a heterologous challenge in a mouse model. This design work delineates the likely requirements and limitations on broadly-protective filoviral CTL vaccines.


Subject(s)
Epitopes, T-Lymphocyte/immunology , Filoviridae Infections/immunology , Filoviridae/immunology , T-Lymphocytes, Cytotoxic/immunology , Viral Vaccines/immunology , AIDS Vaccines/immunology , Animals , Antibodies, Viral/immunology , Computational Biology/methods , Cross Reactions/immunology , Drug Design , Ebola Vaccines/administration & dosage , Ebola Vaccines/immunology , Enzyme-Linked Immunosorbent Assay , Female , Filoviridae/metabolism , Filoviridae Infections/prevention & control , Filoviridae Infections/virology , Hepacivirus/immunology , Humans , Mice , Mice, Inbred C57BL , Survival Analysis , Viral Hepatitis Vaccines/immunology , Viral Proteins/immunology , Viral Vaccines/administration & dosage
15.
Tuberculosis (Edinb) ; 92(3): 194-201, 2012 May.
Article in English | MEDLINE | ID: mdl-22218163

ABSTRACT

The emergence of whole genome sequencing (WGS) technologies as primary research tools has allowed for the detection of genetic diversity in Mycobacterium tuberculosis (Mtb) with unprecedented resolution. WGS has been used to address a broad range of topics, including the dynamics of evolution, transmission and treatment. Here, we have analyzed 55 publically available genomes to reconstruct the phylogeny of Mtb, and we have addressed complications that arise during the analysis of publically available WGS data. Additionally, we have reviewed the application of WGS to the study of Mtb and discuss those areas still to be addressed, moving from global (phylogeography), to local (transmission chains and circulating strain diversity), to the single patient (clonal heterogeneity) and to the bacterium itself (evolutionary studies). Finally, we discuss the current WGS approaches, their strengths and limitations.


Subject(s)
Genome, Bacterial , Mycobacterium tuberculosis/genetics , Bacterial Typing Techniques/methods , Databases, Nucleic Acid , Genetic Variation , Humans , Mycobacterium tuberculosis/classification , Phylogeny , Polymorphism, Single Nucleotide , Sequence Analysis, DNA/methods , Tuberculosis/microbiology
16.
J Gen Virol ; 91(Pt 5): 1194-206, 2010 May.
Article in English | MEDLINE | ID: mdl-20053820

ABSTRACT

Immunological control of hepatitis C virus (HCV) is possible and is probably mediated by host T-cell responses, but the genetic diversity of the virus poses a major challenge to vaccine development. We considered monovalent and polyvalent candidates for an HCV vaccine, including natural, consensus and synthetic 'mosaic' sequence cocktails. Mosaic vaccine reagents were designed using a computational approach first applied to and demonstrated experimentally for human immunodeficiency virus type 1 (HIV-Delta). Mosaic proteins resemble natural proteins, but are assembled from fragments of natural sequences via a genetic algorithm and optimized to maximize the coverage of potential T-cell epitopes (all 9-mers) found in natural sequences and to minimize the inclusion of rare 9-mers to avoid vaccine-specific responses. Genotype 1-specific and global vaccine cocktails were evaluated. Among vaccine candidates considered, polyvalent mosaic sequences provided the best coverage of both known and potential epitopes and had the fewest rare epitopes. A global vaccine based on conserved proteins across genotypes may be feasible, as a five-antigen mosaic cocktail provided 90, 77 and 70% coverage of the Core, NS3 and NS4 proteins, respectively; protein coverage diminished with increased protein variability, dropping to 38% for NS2. For the genotype 1-specific vaccine, the H77 prototype vaccine sequence matched only 50% of the potential epitopes in the population, whilst a polyprotein three-antigen mosaic cocktail increased potential epitope coverage to 83%. More than 75% coverage of all HCV proteins was achieved with a three-antigen mosaic cocktail, suggesting that genotype-specific vaccines could also include the more variable proteins.


Subject(s)
Genetic Variation , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C/prevention & control , T-Lymphocytes/immunology , Viral Hepatitis Vaccines/immunology , Epitopes, T-Lymphocyte/genetics , Epitopes, T-Lymphocyte/immunology , Genotype , Hepatitis C/immunology , Humans , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Viral Nonstructural Proteins/genetics , Viral Nonstructural Proteins/immunology
17.
Bioinformatics ; 24(14): 1639-40, 2008 Jul 15.
Article in English | MEDLINE | ID: mdl-18515277

ABSTRACT

UNLABELLED: We present a suite of on-line tools to design candidate vaccine proteins, and to assess antigen potential, using coverage of k-mers (as proxies for potential T-cell epitopes) as a metric. The vaccine design tool uses the recently published 'mosaic' method to generate protein sequences optimized for coverage of high-frequency k-mers; the coverage-assessment tools facilitate coverage comparisons for any potential antigens. To demonstrate these tools, we designed mosaic protein sets for B-clade HIV-1 Gag, Pol and Nef, and compared them to antigens used in a recent human vaccine trial. AVAILABILITY: http://hiv.lanl.gov/content/sequence/MOSAIC/.


Subject(s)
AIDS Vaccines/chemistry , HIV Infections/prevention & control , HIV-1/genetics , HIV-1/immunology , T-Lymphocytes/metabolism , Technology, Pharmaceutical/instrumentation , Vaccines/chemistry , Algorithms , Antigens/chemistry , Computers , Drug Design , Epitopes/chemistry , Epitopes, T-Lymphocyte/chemistry , HIV Infections/virology , Humans , Internet , Software
18.
J Exp Med ; 205(5): 1009-17, 2008 May 12.
Article in English | MEDLINE | ID: mdl-18426987

ABSTRACT

In a study of 114 epidemiologically linked Zambian transmission pairs, we evaluated the impact of human leukocyte antigen class I (HLA-I)-associated amino acid polymorphisms, presumed to reflect cytotoxic T lymphocyte (CTL) escape in Gag and Nef of the virus transmitted from the chronically infected donor, on the plasma viral load (VL) in matched recipients 6 mo after infection. CTL escape mutations in Gag and Nef were seen in the donors, which were subsequently transmitted to recipients, largely unchanged soon after infection. We observed a significant correlation between the number of Gag escape mutations targeted by specific HLA-B allele-restricted CTLs and reduced VLs in the recipients. This negative correlation was most evident in newly infected individuals, whose HLA alleles were unable to effectively target Gag and select for CTL escape mutations in this gene. Nef mutations in the donor had no impact on VL in the recipient. Thus, broad Gag-specific CTL responses capable of driving virus escape in the donor may be of clinical benefit to both the donor and recipient. In addition to their direct implications for HIV-1 vaccine design, these data suggest that CTL-induced viral polymorphisms and their associated in vivo viral fitness costs could have a significant impact on HIV-1 pathogenesis.


Subject(s)
Gene Products, gag/genetics , HIV-1/genetics , Mutation , Viral Load , Amino Acid Sequence , Base Sequence , Gene Products, gag/chemistry , Gene Products, gag/immunology , HIV-1/immunology , HLA-B Antigens/genetics , HLA-B Antigens/immunology , Histocompatibility Antigens Class I/immunology , Humans , Polymorphism, Genetic , South Africa/epidemiology , Zambia/epidemiology
19.
Nucleic Acids Res ; 36(Database issue): D512-6, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18025038

ABSTRACT

The hepatitis C virus (HCV) is a significant public health threat worldwide. The virus is highly variable and evolves rapidly, making it an elusive target for the immune system and for vaccine and drug design. Presently, approximately 50 000 HCV sequences have been published. A central website that provides annotated sequences and analysis tools will be helpful to HCV scientists worldwide. The HCV sequence database collects and annotates sequence data, and provides them to the public via a website that contains a user-friendly search interface and a large number of sequence analysis tools, following the model of the highly regarded and widely used Los Alamos HIV database. The HCV website can be accessed via http://hcv.lanl.gov and http://hcv-db.org.


Subject(s)
Databases, Genetic , Hepacivirus/genetics , Genes, Viral , Genotype , Hepatitis C/virology , Humans , Internet , Sequence Analysis, Protein , Sequence Analysis, RNA , Software , Viral Proteins/chemistry , Viral Proteins/genetics
20.
AIDS ; 21(18): 2387-97, 2007 Nov 30.
Article in English | MEDLINE | ID: mdl-18025875

ABSTRACT

BACKGROUND: Differential protein targeting by HIV-specific CD8 T cells is associated with disparate plasma viral loads; however, it is unclear if the quality of these responses differs depending upon the specificity of the targeted epitopes. METHODS: We examined HIV-specific CD8 T-cell responses in HIV-infected adolescents carrying either an HLA class I allele associated with a favorable prognosis (HLA-B*57) or an allele associated with usual disease progression (HLA-B*35 or HLA-B*53) using interferon-gamma ELISpot and ICS assays. RESULTS: In an interferon-gamma ELISpot assay, p24 was the dominant protein targeted by B*57 carriers while responses to Nef dominated in B*35 or B*53 positive carriers. This differential protein targeting did not change during 4 years of follow-up. In these chronically infected adolescents, there were no significant differences in the quality of the immunodominant T-cell responses between the B*57 and B*35/B*53 carriers as measured by peptide avidity, degranulation, and immune memory markers. There was a trend towards higher expression of interleukin-2 from B*57-KF11 restricted CD8 T cells although this difference was not significant. Nevertheless both B*57 and B*35/53-restricted responses were relatively potent as reflected by the propensity of CD8 T cells to escape in p24 and Nef, respectively. CONCLUSIONS: Differential protein targeting rather than the quality of T-cell responses appears to be a major distinguishing feature of HIV-specific CD8 T cells induced in B*57 carriers. These data suggest that viral fitness costs associated with CD8 T-cell pressure is an important factor determining differences in the viral load among HIV-infected patients.


Subject(s)
HIV Infections/immunology , HIV-1 , HLA Antigens/immunology , HLA-B35 Antigen/immunology , Adolescent , Amino Acid Sequence , CD8-Positive T-Lymphocytes/immunology , Chronic Disease , Cross-Sectional Studies , Disease Progression , Female , Follow-Up Studies , Gene Products, gag/genetics , Gene Products, gag/immunology , Genetic Predisposition to Disease , HIV Core Protein p24/genetics , HIV Core Protein p24/immunology , HIV Infections/genetics , HIV Infections/virology , HIV-1/genetics , HIV-1/immunology , HLA-B Antigens/immunology , Humans , Immunodominant Epitopes/genetics , Immunodominant Epitopes/immunology , Interleukin-2/biosynthesis , Molecular Sequence Data , Mutation , Prognosis , Viral Load , nef Gene Products, Human Immunodeficiency Virus/genetics , nef Gene Products, Human Immunodeficiency Virus/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...